

## belzutifan (WELIREG)

### Diagnoses Considered for Coverage:

- Von Hippel-Lindau (VHL) disease in patients who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET)
- Advanced Renal Cell Carcinoma (RCC)

### Coverage Criteria:

#### For diagnosis of von Hippel-Lindau (VHL) disease:

- Patient has VHL gene mutation, **and**
- One of the following VHL tumor types:
  - a. Renal cell carcinoma (RCC), or
  - b. Hemangioblastoma, or
  - c. Pancreatic neuroendocrine tumor (pNET), **and**
- One of the following:
  - Being used as a single agent, or
  - For pNET tumors: Being used as a single agent or concurrently with octreotide or lanreotide,**and**
- Dose does not exceed 120 mg per day.

#### For diagnosis of advanced renal cell carcinoma (RCC):

- Patient has been previously treated with:
  - a PD-1 (programmed death receptor-1) or PD-L1 (programmed death-ligand 1) inhibitor, **and**
  - a VEGF-TKI (vascular endothelial growth factor receptors-tyrosine kinase inhibitor)**and**
- Being used as a single agent, **and**
- Dose does not exceed 120 mg per day

Coverage Duration: one year

#### REFERENCES:

1. Prescribing Information. Welireg. Merck Sharp & Dohme Corp. December 2023.
2. Welireg. National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium. February 2024. Available by subscription at: [www.nccn.org](http://www.nccn.org).
1. National Comprehensive Cancer Network. Kidney Cancer (Version 2.2024 - January 3, 2024). Available at [www.nccn.org](http://www.nccn.org).

Effective Date: 02/28/2024